Celdara Medical NYC would like to invite you to attend our Pitch competition and Networking event which will be held on December 14th, 2016 at the New York Blood center.
Come listen to Celdara Medical NYC Interns pitch company development strategies for early stage technologies and stay for the post-pitch networking session.
Pitch Competition: 3:30-5:00 pm
Networking Reception: 5:00-6:30 pm Sponsored By Genmab
Kathleen Denis, Associate VP at Rockefeller University;
Peter Donnelly, Director at OITD Stony Brook University & Manager of Accelerate LI;
Sam Kongsamut, Executive Director at Institute for Life Science Entrepreneurship (ILSE)
Derek Brand, CEO at Quicksilver Genomics
Sam Hall, Principal at Apple Tree Partners
Bruce Conway, Program Director at Rockefeller University
Christopher Halliday, Partner at Morgan Lewis & Bockius
About Celdara Medical
Celdara Medical builds lasting partnerships with inventors and their institutions, and provides the developmental, financial, and business acumen to bridge the gap between discovery and clinical impact. Celdara has been in the New York City biotech community since 2014 and specializes in therapeutic development across all disease spaces. http://www.celdaramedical.com
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.